James / Martini Current Topics in Experimental Endocrinology

Volume 2
1. Auflage 2013
ISBN: 978-1-4832-1734-5
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, 264 Seiten

Current Topics in Experimental Endocrinology, Volume 2 covers major developments in the ever-expanding field of endocrinology. The book discusses the progress in cyclic nucleotide research; the hypothalamic control of the anterior pituitary hormone secretion-characterized hypothalamic hypophysiotropic peptides; and the pituitary-ovarian interrelationships in the rat. The text also describes the melatonin and the endocrine role of the pineal organ; the integration of the secretory control mechanisms for insulin, glucagon, and growth hormone; and the biological activity of somatomedin. The chemistry and physiology of parathyroid hormone, calcitonin, and vitamin d; and the physicochemical properties and activities of luteinizing hormone and human chorionic gonadotropin are also encompassed. Endocrinologists, physiologists, and students taking related courses will find the book invaluable.

Autoren/Hrsg.

James, V. H. T.

Martini, L.

Inhaltsverzeichnis

1;Front Cover;1
2;Current Topics in Experimental Endocrinology;4
3;Copyright Page;5
4;Table of Contents;6
5;LIST OF CONTRIBUTORS;10
6;PREFACE;12
7;Chapter 1. Recent Progress in Cyclic Nucleotide Research;14
7.1;I. Introduction;15
7.2;II. Adenylyl Cyclase;17
7.3;III. Cyclic Nucleotide Phosphodiesterases;28
7.4;IV. Mechanism of Action of Cyclic 36
7.5;V. Cyclic GMP;40
7.6;VI. Summary;42
7.7;References;44
8;Chapter 2. Hypothalamic Control of Anterior Pituitary Hormone Secretion—Characterized Hypothalamic-Hypophysiotropic Peptides;50
8.1;I. Introduction;51
8.2;II. Physiology of Hypothalamic-Releasing and Release-Inhibiting Factors Acting on the Anterior Pituitary;51
8.3;III. Mechanism of Action of Hypothalamic-Releasing Factors;54
8.4;IV. Peripheral Control of Pituitary Secretion;57
8.5;V. Thyrotropin-Releasing Factor (TRF);58
8.6;VI. Luteinizing Hormone-Releasing Factor (LRF);69
8.7;VII. Hypothalamic Control of Growth Hormone Secretion;78
8.8;VIII. Hypothalamic Control of Melanocyte-Stimulating Hormone (MSH);80
8.9;IX. Concluding Remarks;81
8.10;References;81
9;Chapter 3. Pituitary-Ovarian Interrelationships in the Rat;86
9.1;I. Introduction;86
9.2;II. Ovarian Regulation of Gonadotropin Secretion;87
9.3;III. Ovarian Regulation of Prolactin Secretion;101
9.4;IV. Regulation of Corpus Luteum Function;111
9.5;References;116
10;Chapter 4. Melatonin and the Endocrine Role of the Pineal Organ;120
10.1;I. Introduction;120
10.2;II. Melatonin Biosynthesis;121
10.3;III. Melatonin Metabolism;126
10.4;IV. Melatonin and Pinealectomy-Induced Endocrine Changes;128
10.5;V. Other Possible Sources of Melatonin;134
10.6;VI. Conclusions;135
10.7;References;136
11;Chapter 5. Integration of the Secretory Control Mechanisms for Insulin, Glucagon, and Growth Hormone;142
11.1;I. Introduction;143
11.2;II. Secretory Control Mechanisms;143
11.3;III. Mutual and Autoregulation of Secretion of the Three Hormones;148
11.4;IV. Metabolic Actions;150
11.5;V. Hormonal Response to Meals;153
11.6;VI. Hormonal Milieu in Altered Physiological and Pathological States;155
11.7;VII. Relative Importance of the Three Hormones in Metabolism;159
11.8;VIII. Concluding Remarks;161
11.9;References;162
12;Chapter 6. Somatomedin;168
12.1;I. Introduction;169
12.2;II. Bioassay of Somatomedin;169
12.3;III. Somatomedin Levels in Disorders of Growth;173
12.4;IV. Purification of Somatomedin;175
12.5;V. Biological Actions of Somatomedin in Vitro;180
12.6;VI. Relation between Somatomedin and Other Growth Factors;184
12.7;VII. Conclusions;187
12.8;References;188
13;Chapter 7. Parathyroid Hormone, Calcitonin, and Vitamin D;192
13.1;I. Introduction;192
13.2;II. Parathyroid Hormone;193
13.3;III. Calcitonin;196
13.4;IV. Vitamin D;200
13.5;References;204
14;Chapter 8. Luteinizing Hormone and Human Chorionic Gonadotropin: Structure and Activity;208
14.1;I. Luteinizing Hormone;210
14.2;II. Human Chorionic Gonadotropin;236
14.3;References;251
15;SUBJECT INDEX;260

Leseproben

Recent Progress in Cyclic Nucleotide Research

S.J. Strada and G.A. Robison,     Program in Pharmacology, University of Texas Medical School at Houston, Houston, Texas

Publisher Summary

Adenosine 3’, 5’-monophosphate (cyclic AMP) is formed from ATP through the action of adenylyl cyclase, which seems to be an integral component of the cell membrane in most cells. Hormones appear to stimulate the enzyme by interacting with specific receptors on the external surface of the membrane. Calcium is involved in several ways; it is required for cyclase activation by at least one hormone (ACTH), and there is evidence that some hormones can influence calcium transport independently of their effect on cyclise. Fluoride stimulates adenylyl cyclise activity in broken cell preparations of most eukaryotic cells, but so far, this has not led to any important insights into the mechanism of hormonal stimulation. Cyclic AMP is metabolized to 5’-AMP under the catalytic influence of one or more phosphodiesterases. Phosphohpids, ions, and one or more endogenous proteins are involved in regulating phosphodiesterase activity, and cyclic AMP itself appears capable of inducing the formation of at least one isozyme. Most of the physiologically important effects of cyclic AMP in higher forms are the result of protein kinase activation. Cyclic AMP-dependent protein kinases are composed of catalytic and regulatory subunits.

I  Introduction

II  Adenylyl Cyclase

A  Relation to Hormone Receptors

B  Possible Importance of Calcium

C  Phospholipids

D  The Fluoride Response

E  The Effect of Guanyl Nucleotides

F  Effects of Prostaglandins

G  The Effect of Cholera Toxin

H  Inhibitors of Adenylyl Cyclase

III  Cyclic Nucleotide Phosphodiesterases

A  Multiple Molecular Forms

B  Endogenous Modulators of Cyclic Nucleotide Phosphodiesterases

IV  Mechanism of Action of Cyclic AMP

A  Protein Kinase Activation

B  Possible Importance of Microtubules

C  Other Possible Mechanisms

V  Cyclic GMP

VI  Summary

References

I Introduction

Adenosine 3',5'-monophosphate (cyclic AMP) was discovered in 1956 in the course of endocrinological research (see Sutherland and Rall, 1960, for an early review). Most of the research on this substance for the next 10 years or so was concerned directly or indirectly with its role as a regulator of differentiated eukaryotic cell function. It was shown first to mediate the hepatic glycogenolytic effect of glucagon and epinephrine, and was eventually recognized as a second messenger mediating many of the effects of a variety of other hormones, including ACTH (adrenocorticotropic hormones), TSH (thyroid-stimulating hormone), vasopressin, luteinizing hormone, MSH (melanocyte-stimulating hormone), and parathyroid hormone. This aspect of the subject has been discussed in a number of recent monographs and review articles (e.g., Robison ., 1971 a,b; Hardman ., 1971; Cheung, 1972; Gill, 1972; Major and Kilpatrick, 1972; Greengard ., 1972a; Sutherland, 1972).

One of the reasons for the slow initial progress in understanding the role of cyclic AMP was that methodology was difficult, but this is no longer the most important limiting factor (Greengard ., 1972b; Chasin, 1972). Cyclic AMP has now transcended its endocrinological beginning and has been shown to function in almost all animal species, including bacteria and other unicellular organisms. In and other gram-negative bacteria, cyclic AMP appears to be required for the synthesis of a number of inducible enzymes, and the ability of glucose to suppress cyclic AMP formation appears to account satisfactorily for catabolite repression (Pastan and Perlman, 1972). Cyclic AMP has also been implicated in lysogeny (Hong ., 1971) and bacterial transformation (Wise ., 1973). In certain species of cellular slime molds, cyclic AMP appears to be responsible for initiating the aggregation of slime mold amebae, leading to the formation of a multicellular organism (Bonner, 1971).

Evidence has now begun to accumulate to suggest that cyclic AMP may also play an important role during the growth and development of higher organisms. Although data are presently insufficient to define this role precisely, it would appear that in some types of cells reduced levels of cyclic AMP are needed to permit rapid cell division, whereas higher levels are associated with differentiation (Weiss and Strada, 1973). Changes in cyclic AMP during the cell cycle are now being explored (Willingham ., 1972; Burger ., 1972), and an important complementary role for cyclic GMP (guanosine 3',5'-monophosphate) has been suggested (Hadden ., 1972). It now seems possible that reduced levels of cyclic AMP or perhaps increased levels of cyclic GMP are involved in a number of proliferative disorders, including psoriasis (Voorhees ., 1972) and certain forms of cancer (Otten ., 1972). Cyclic nucleotides may also play an important series of roles during the immune response (see, for example, Orange ., 1971; Parker, 1972; Hadden ., 1972; Bourne ., 1973), although it may be some time before these roles become clarified.

It is no longer possible to discuss intelligently all aspects of cyclic nucleotide research in a single review article. Our purpose in this review will be to summarize what is known about the formation, metabolism, and action of cyclic AMP, with major emphasis on eukaryotic cells. In all cells studied, cyclic AMP is formed from ATP through the catalytic influence of adenylyl cyclase, and is metabolized to 5'-AMP under the influence of one or more phosphodiesterases (Fig.1). The intracellular level of cyclic AMP is therefore determined by the rates of these reactions, as well as by the rate at which it is released into the extracellular space. Most of the effects of cyclic AMP are poorly understood, but the glycogenolytic and lipolytic effects have been shown to involve the activation of a protein kinase. This may be the mechanism of many and perhaps most of the physiologically important effects of cyclic AMP in differentiated eukaryotic cells.

Fig. 1 Reactions involved in the formation and metabolism of cyclic AMP.

II Adenylyl Cyclase

A Relation to Hormone Receptors

The particulate nature of hepatic adenylyl cyclase was established by early experiments of Sutherland and Rall and their colleagues (Sutherland and Rall, 1960; Sutherland ., 1962). Adenylyl cyclase in most eukary-otic cells appears to occur predominantly in the plasma membrane (Davoren and Sutherland, 1963), although significant activity may also occur in other membranous components in some cells, such as the sarcoplasmic reticulum in muscle cells (Levey, 1971a). The ability of glucagon to stimulate hepatic adenylyl cyclase and of ACTH to stimulate the adrenal enzyme led to the idea that the receptors for some hormones might be closely related to adenylyl cyclase (Sutherland and Rall, 1960).

Based on these and other observations, a model was developed according to which the protein component of the adenylyl cyclase system was envisioned as a two-component system embedded in the lipid matrix of the cell membrane (Robison ., 1967). A regulatory subunit possessing receptors for one or more hormones was postulated to be in contact with the extracellular space, with a catalytic subunit in contact with cytoplasmic ATP. An effective interaction between hormone and receptor on the external surface of the membrane could thus lead to a conformational perturbation leading to a change in catalytic activity on the inner surface of the membrane. A variant of this model postulated a third component, a “transducer” interposed between an external “discriminator” and an internal “amplifier” (Rodbell, 1972). Such models are perhaps best viewed in the light of the fluid mosaic theory of...